Accredited: AATD liver care journey

The alpha-1 antitrypsin deficiency liver care journey: From early signs to effective strategies

To earn your CME credit, watch the full session and then complete the knowledge assessment and evaluation form.

Would you like to self-assess your knowledge before watching? Click here to access the quiz.

ACCME, ACPE, and ANCC accredited (1 CME credit)

View transcript.

Symptom-free doesn’t mean disease-free. Watch this accredited symposium, delivered at the European Association for the Study of the Liver (EASL) Congress 2025, for expert advice on diagnosis and management of alpha-1 antitrypsin deficiency-associated liver disease – a complication that can exist without overt symptoms.

Hear about:

• The role of the Pi*ZZ genotype as a liver disease predictor
• Bringing together the right specialists for an optimal patient-centered service
• Emerging therapies for alpha-1 antitrypsin deficiency-associated liver disease
• First-hand experience of diagnosis and treatment, from a person with alpha-1 antitrypsin deficiency

How much do you know about alpha-1 antitrypsin deficiency? Answer these four questions to find out. We’ll ask you the questions again after you’ve watched the symposium to see what you recall.

If you're having trouble accessing this quiz, try refreshing your browser. If the issue persists, please enable browser cookies and remove any ad blockers in your settings, and refresh the page again.

Meet the experts

Rohit Loomba, MD

Rohit Loomba is a professor of medicine and the Chief of the Division of Gastroenterology and Hepatology at the University of California, San Diego, USA. He is the founding director of the UCSD MASLD Research Center and a global leader in translational research and clinical trial design for nonalcoholic steatohepatitis and liver disease assessment using advanced imaging.

Disclosures: 89bio, Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cascade Pharmaceuticals, Eli Lilly and Company, Galectin Therapeutics, Gilead, Glympse Bio, Hanmi Pharmaceutical, Inipharm, Intercept Pharmaceuticals, Inventiva, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Lipidio Pharma, LipoNexus, Madrigal Pharmaceuticals, Merck, NeuroBo Pharmaceuticals, Novo Nordisk, Pfizer, Sagimet Biosciences, Sonic Incytes, Takeda, Terns Pharmaceuticals, and Viking Therapeutics.

Pavel Strnad, MD

Pavel Strnad is a full professor and leading physician at the University Hospital Aachen, Germany. He heads his own research lab focusing on translational gastroenterology and the European initiative for the study of alpha1-antitrypsin deficiency-associated liver disease. His interests include metabolic liver disease, liver cirrhosis and its complications, as well as the analysis of complex datasets. His clinical focus is on emerging drugs, end-stage liver disease, and liver transplantation.

Disclosures: Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, CSL Behring, Dicerna Pharmaceuticals, Grifols, GSK, Intellia Therapeutics, Novo Nordisk, Ono Pharmaceutical, Takeda, and Vertex Pharmaceuticals.

Alice Turner, MBChB

Alice Turner is a professor in respiratory medicine at the University of Birmingham, with clinical work focusing on AATD and chronic obstructive pulmonary disease. She runs the largest AATD clinic and cohort in the UK, is the research lead for the European pulmonary AATD registry (EARCO), Chair of the ERS AATD guidelines group, a major contributor to the European AATD liver registry initiated by EASL, and is an Alpha-1 Foundation board member.

Disclosures: AIRNA, AstraZeneca, Beam Therapeutics, Chiesi Farmaceutici, CSL Behring, Grifols, GSK, MSD, Sanofi, Takeda, and Vertex Pharmaceuticals.

Virginia Clark, MD

Virginia Clark is a Clinical Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Florida, Gainesville, USA. Her research interest is liver disease in AATD, and she led a natural history study to evaluate the prevalence of liver disease in AATD. She has an active clinical practice for patients with AATD and an established clinical research program for new investigational agents for AATD. Clark is a member of the Alpha-1 Foundation Board of Directors, which is a patient-led organization whose mission is to find a cure for AATD and improve the lives of those affected by the genetic condition.

Disclosures: 89bio, BioMarin Pharmaceutical, Hanmi Pharmaceutical, Novo Nordisk, and Takeda.

Accreditation details